To investigate the effect of Olibanum Gum, Silybum marianum seed and Urtica dioica leaf extracts mixture on blood sugar and glycosylated hemoglobin in type 2 diabetic patients: a double blind, randomized, placebo controlled trial.

Effects of Olibanum Gum, Silybum marianum seed and Urtica dioica leaf mixture on type 2 diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201502011157N9

Enrollment

Registered

2015-03-06

Start date

2015-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Herbal Drug: 600 mg 3 times a day after food. Intervention 2: Placebo: 600 mg 3 times a day after food.

Treatment - Drugs

Placebo

Herbal Drug: 600 mg 3 times a day after food

Placebo: 600 mg 3 times a day after food

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Type 2 diabetic patients; aged 40 to 60 years; fasting blood glucose levels from 150 to 180 mg/dL; blood glycosylated hemoglobin levels from 7.5 to 8.5 percent; under therapy of oral anti-hyperglycemic drugs maximum 10 mg glyburide and 1000 mg metformin daily. Exclusion criteria: Patients receiving insulin therapy; patients with cardiao vascular, renal, hepatic, hematological, hypothyroidism, vertigo and seizure diseases; patients with a history of gallstones or gall bladder surgery; patients under estrogen, steroid, beta-blocker and thiazide therapy; pregnant women; women planning for pregnancy and breast-feeding women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level will be determined in laboratory by commercially available kit.;Glycosylated hemoglobin (HbA1c). Timepoint: At starting of the study and after 3 months. Method of measurement: HbA1c percent will be determined in laboratory by commercially available kit.	—

Secondary

Measure	Time frame
Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercially available kit.;Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercially available kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase (AST). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood AST level will be determined in laboratory by commercially available kit.;Alanine aminotransferase (ALT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALT level will be determined in laboratory by commercially available kit.;Blood urea nitrogen (BUN). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood BUN level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level will be determined in laboratory by commercially available kit.	—

Measure

Time frame

Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level will be determined in laboratory by commercially available kit.;Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level will be determined in laboratory by commercially available kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level will be determined in laboratory by commercially available kit.;Aspartate aminotransferase (AST). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood AST level will be determined in laboratory by commercially available kit.;Alanine aminotransferase (ALT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALT level will be determined in laboratory by commercially available kit.;Blood urea nitrogen (BUN). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood BUN level will be determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level will be determined in laboratory by commercially available kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level will be determined in laboratory by commercially available kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Fallah Huseini

Institute of Medicinal Plants

huseini_fallah@yahoo.com+98 263476401020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026